Novartis Poised To Grow Despite $9bn In LOEs Coming, CEO Says

CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.

stairs growth
Novartis laid out a path for growth during an R&D day • Source: Alamy

Novartis AG CEO Vas Narasimhan laid out the company's near- and long-term growth plans to investors, committing to delivering compound annual growth (CAGR) of 4% through 2026 despite the anticipated loss of several top-selling brands to generic competition. The company presented its growth strategy and the key brands and pipeline assets that will drive that growth during a five-hour R&D day on 2 December.

"From 2020 to 2026, the Novartis story is driven by six major brands and then some additional pipeline launches, where...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.